Liarozole

CAS No. 115575-11-6

Liarozole( R75251 dihydrochloride )

Catalog No. M23335 CAS No. 115575-11-6

Liarozole is a cytochrome P450 (CYP450) dependent inhibitor, orally active, it also a potent inhibitor of estrogen (via inhibition of aromatase) and testicular androgen synthesis (inhibition of 17 ,20-lyase).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 178 In Stock
10MG 295 In Stock
25MG 502 In Stock
50MG 709 In Stock
100MG 1008 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Liarozole
  • Note
    Research use only, not for human use.
  • Brief Description
    Liarozole is a cytochrome P450 (CYP450) dependent inhibitor, orally active, it also a potent inhibitor of estrogen (via inhibition of aromatase) and testicular androgen synthesis (inhibition of 17 ,20-lyase).
  • Description
    Liarozole is a cytochrome P450 (CYP450) dependent inhibitor, orally active, it also a potent inhibitor of estrogen (via inhibition of aromatase) and testicular androgen synthesis (inhibition of 17 ,20-lyase).Liarozole dihydrochloride is an imidazole derivative;?it is being investigated as a non-hormonal agent in prostate cancer and in the treatment of various other cancers and skin disorders.?(In Vitro):Liarozole (0.01~10 μM; 9 days; MCF-7 cells) inhibits cells proliferation.Liarozole (1 μM; 4 days; mesenchymal cells) completely inhibits chondrogenesis.(In Vivo):Liarozole (5-20 mg/kg; p.o.; 3 days) reverses the vaginal keratosis caused by estrogen stimulation.Liarozole (40 mg/kg; p.o.; 21 days) reduces tumor burden substantially.
  • In Vitro
    Liarozole (0.01~10 μM; 9 days; MCF-7 cells) inhibits cells proliferation.Liarozole (1 μM; 4 days; mesenchymal cells) completely inhibits chondrogenesis. Cell Proliferation Assay Cell Line:MCF-7 cells Concentration:0.01~10 μM Incubation Time:9 days Result:Had an effect of 35% inhibition at 10 μM on cell proliferation.Cell Differentiation Assay Cell Line:Mesenchymal cells Concentration:1 μM Incubation Time:4 days Result:Completely inhibited chondrogenesis.
  • In Vivo
    Liarozole (5-20 mg/kg; p.o.; 3 days) reverses the vaginal keratosis caused by estrogen stimulation.Liarozole (40 mg/kg; p.o.; 21 days) reduces tumor burden substantially. Animal Model:Ovariectomized rats Dosage:5~20 mg/kg Administration:P.o.; 3 days Result:Reversed the vaginal keratosis caused by estrogen stimulation.Animal Model:SCID miceDosage:40 mg/kg Administration:P.o.; 21 days Result:Inhibited tumor growth and survival.
  • Synonyms
    R75251 dihydrochloride
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    P450
  • Recptor
    CYP450
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    115575-11-6
  • Formula Weight
    308.76
  • Molecular Formula
    C17H13ClN4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    ClC1=CC(C(C2=CC=C3NC=NC3=C2)N4C=CN=C4)=CC=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bryson HM, et al. Liarozole. Drugs Aging. 1996 Dec;9(6):478-84; discussion 485.
molnova catalog
related products
  • CDD3506

    CDD3506 increases high-density lipoprotein cholesterol by targeting hepatic CYP3A.

  • Ginsenoside F1

    Ginsenoside F1,an enzymatically modified derivative of ginsenoside Rg1, protection from ultraviolet-B-induced apoptosis is tightly correlated with ginsenoside-F1-mediated inhibition of ultraviolet-B-induced downregulation of Bcl-2 and Brn-3a expression.

  • 1-Aminobenzotriazole

    1-Aminobenzotriazole (ABT) is a non-specific cytochrome P450 (CYP) inhibitor.